Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Idiopathic pulmonary fibrosis primarily occurs in older adults and the disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-gradefevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy,laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone,and N-acetyl cysteine are used alone or combination for the treatment

Key Developments: 

Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.

• In August 2017, FibroGen, Inc. announced positive topline results from the companys Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
• In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).